Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ELND005 · AZD-103

Small molecule · Inhibitor · developed by OPKO Health

Phase 2 Most advanced trial (none active)
OPK Developer
3 Registered trials

What is ELND005?

ELND005 (scyllo-inositol, also called scyllitol) is an oral stereoisomer of inositol that crosses the blood-brain barrier. It is reported to inhibit amyloid beta plaque formation in the brain, though its precise mechanism is not established. It is studied in Alzheimer's disease and Down syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD-103, scyllo-inositol
Drug type
Small molecule
Mechanism
Inhibitor
Pathways
amyloid beta plaque formation
Therapy area
Neurology
Developer
OPKO Health, Inc. (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
1VS4X81277

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01791725 Phase 2 Down Syndrome Completed OPK
NCT01766336 Phase 2 Alzheimer's Disease Terminated OPK
NCT00934050 Phase 2 Alzheimer's Disease Completed OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's DiseaseDown Syndrome

More from OPKO Health

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.

Follow OPK, the company behind ELND005

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.